SCHEMBL17809659

SCHEMBL17809659

COCCOCCOCCOC(=O)NCCCCCCNC(=O)OCCOCCOCCOc1ccc(CCCCNC(=N)NC(=O)c2nc(Cl)c(N)nc2N)cc1

nearest known ligand 0.51

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
SCNN1A P37088 20/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17809678 1.00 SCNN1A (0.51) SCNN1A
SCHEMBL17809405 0.99 SCNN1A (0.52) SCNN1A
SCHEMBL16383655 0.97 SCNN1A (0.54) SCNN1A
SCHEMBL17809366 0.97 SCNN1A (0.54) SCNN1A
SCHEMBL17809444 0.96 SCNN1A (0.52) SCNN1A
SCHEMBL16383771 0.96 SCNN1A (0.55) SCNN1A
SCHEMBL16383862 0.96 SCNN1A (0.55) SCNN1A
SCHEMBL9913767 0.95 SCNN1A (0.56) SCNN1A
SCHEMBL9913758 0.95 SCNN1A (0.56) SCNN1A
SCHEMBL17806168 0.94 SCNN1A (0.51) SCNN1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9656972-B2 Compounds for treatment of cystic fibrosis THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2017-05-23 US disclosed
US-20160159754-A1 COMPOUNDS FOR TREATMENT OF CYSTIC FIBROSIS THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH 2016-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160159754-A1 COMPOUNDS FOR TREATMENT OF CYSTIC FIBROSIS CFTR, ELANE, OTC SCNN1A 87/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.